Ama-Menin Inhibitors: Ukwelapha Okumangalisayo Kwe-Acute Myeloid Leukemia
I-Acute myeloid leukemia (AML) iyinkinga yegazi eyinkimbinkimbi futhi ehlukahlukene ebonakala ngokwanda kwamaseli e-myeloid progenitor. Naphezu kwentuthuko ekwelapheni, ukwelapha i-AML kuseyinselele, ikakhulukazi ezigulini ezinezinkinga ezithile zofuzo. Izifundo zakamuva eziqokonyiswe kumagazini Igazi kugcizelela ukubaluleka kwezokwelapha kwama-Menin inhibitors, kugqamisa amandla awo okuguqula ukwelashwa kwe-AML.
Indima Ye-Epigenetics Ku-AML
Ukuguqulwa kwe-epigenetic, njenge-DNA methylation kanye nokuguqulwa kwe-histone, kuyizinguquko eziguqukayo ezilawula ukuvezwa kwezakhi zofuzo ngaphandle kokushintsha ukulandelana kwe-DNA. Lezi zinguquko zidlala indima ebalulekile ekuthuthukisweni kwe-AML. Ukuqondisa lezi zindlela ze-epigenetic eziguqukayo kunikeza indlela entsha yokwelapha.
Ama-Histone, amaprotheni abalulekile ekupakishweni kwe-DNA, adlula ekuguqulweni kwangemva kokuhumusha njenge-acetylation kanye ne-methylation, okuthonya ukubhalwa kwezakhi zofuzo. I-Menin, iphrotheni ye-scaffolding ebhalwe yi-MEN1 gene, ibalulekile ekulawulweni kwe-epigenetic. Isebenzisana ne-histone methyltransferase KMT2A kanye nabanye abalingani ukulawula ukuvezwa kwezakhi zofuzo. Ku-AML, i-Menin yenza kube lula izinhlelo zokubhalwa kwezakhi zofuzo ezibangelwa umdlavuza, ikakhulukazi ngokwandiswa kwezakhi zofuzo ze-HOXA kanye ne-MEIS1, okuyiziqhubi ezibalulekile ku-KMT2A-rearranged kanye ne-NPM1-mutated AML.
Ama-Menin Inhibitors: Impumelelo Ekwelashweni Kwe-AML
Ama-Menin inhibitors angama-molecule amancane akhetheke kakhulu aklanyelwe ukuphazamisa ukusebenzisana phakathi kwe-Menin ne-KMT2A, ngaleyo ndlela avimbele izindlela zokubhalwa kwe-oncogenic. Lawa ma-inhibitors abonise ukusebenza kahle okuphawulekayo ezifundweni zangaphambi kokwelashwa kanye nezemitholampilo, ikakhulukazi kwi-KMT2A-rearranged kanye ne-NPM1-mutated AML, ezihlanganisa isethi ebalulekile yamacala e-AML.
I-Menin inhibitor yokuqala, i-revumenib (SNDX-5613), ivunyelwe ukusetshenziswa emtholampilo, kanti eminye eminingana, okuhlanganisa i-ziftomenib (KO-539) kanye ne-bleximenib, ihlolwe emtholampilo. Isilingo se-AUGMENT-101 sibonise ukuthi i-revumenib ifinyelele izinga lokuphendula eliphelele (ORR) elingu-53% ku-relapse noma refractory (R/R) AML, enemiphumela emibi elawulekayo njenge-QTc prolongation and differentiation syndrome. Ngokufanayo, imiphumela yokuqala evela ezivivinyweni ze-KOMET-001 kanye ne-KOMET-008 ezihlola i-ziftomenib ibonise amazinga okukhululwa athembisayo kanye namaphrofayili okuphepha.
Izindlela zokwelapha ezihlanganisiwe nazo ziyahlolwa ukuze kuthuthukiswe ukusebenza kahle kwama-Menin inhibitors. Izifundo ezihlanganisa i-revumenib nama-hypomethylating agents afana ne-azacitidine kanye ne-venetoclax zibike amazinga okusabela asondela ku-100% ezigulini ze-AML eziphilile nezingafaneleki, yize kudingeka izifundo ezengeziwe ngamaqembu amakhulu.
Iziqondiso Zokuphepha Nesikhathi Esizayo
Ama-Menin inhibitors ngokuvamile abonisa amaphrofayili okuphepha amahle, kanti imiphumela eminingi emibi iyalawuleka futhi iyalungiseka. Izehlakalo ezivamile ezimbi zifaka phakathi izimpawu zesisu, i-cytopenia, kanye ne-differentiation syndrome. Izimpawu zokwelapha ezithuthukisiwe ezinikezwe yi-US FDA ku-revumenib kanye ne-ziftomenib zigcizelela ukubaluleka kwama-Menin inhibitors ekubhekaneni nezidingo ezingakahlangatshezwani nokwelashwa kwe-AML.
Imininingwane yezokwelapha ethembisayo kuma-Menin inhibitors iphawula isinyathelo sokuguqula ukwelashwa kwe-AML, inikeza ithemba ezigulini ezinezinhlobo zezakhi zofuzo eziyinselele emlandweni. Njengoba ucwaningo luqhubeka, lezi zindlela zokwelapha zilungele ukuchaza kabusha izinga lokunakekelwa kwe-AML.
I-BIOOCUS International Medical Center isalokhu izibophezele ekusebenziseni intuthuko esezingeni eliphezulu njengezithibi ze-Menin ukuze inikeze ukwelashwa okusha nokusebenzayo ezigulini emhlabeni jikelele.